The 26th of March 2024 RWE4Decisions webinar discussed the revision of the 2020 paper “Real-world Evidence to Support Payer/HTA Decisions about Highly Innovative Technologies in the EU – Actions for Stakeholders”, available here.
Together with the RWE4Decisions Learning Network, a new set of Actions for each stakeholder group has been drafted and presented at the webinar. The Actions aim to support generation of better Real-World Evidence for HTA and Payer decision-making, looking at the EU and national policy and system changes over the past 5 years.
Following the webinar, a public consultation on the draft new Stakeholder Actions will be launched in April and run until June. The final Actions will be presented at the 14 November 2024 Annual RWE4Decisions Symposium in Brussels.
x
PROGRAMME
x
Welcome from the co-moderators
-
Karen FaceyRWE4Decisions Facilitator
Ashley JaksaMarket Access Scientific Strategy Lead, Aetion
Reviewing the RWE4Decisions 2020 “Actions for Stakeholders” paper
-
Karen FaceyRWE4Decisions Facilitator
Presentations
-
New draft actions for national HTA/Payers and collaborative initiatives
Piia RannanheimoChief Specialist, Finnish Medicines Agency (Fimea) -
New draft actions for the Pharmaceutical Industry
Matias OlsenSenior Manager Public Affairs & Policy, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Panel discussion
-
Niklas HedbergChief Pharmacist, Dental and Pharmaceutical Benefits Agency (TLV)
Antonella CardoneCEO, Cancer Patients Europe
Q&A with audience
Closing remarks & next steps
Public Consultation on the new draft RWE4Decisions Stakeholder Actions
-
Karen FaceyRWE4Decisions Facilitator
